Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.

ABSTRACT:

Background

Primary resistance to immune checkpoint inhibitors (ICIs) remains a major challenge in patients with advanced non-small-cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) expression ≥50%. The benefit of continuing ICIs beyond progression in combination with chemotherapy is unclear.

Patients and methods

This multicenter retrospective study included patients with advanced NSCLC and PD-L1 ≥50% treated with first-line ICI monotherapy at five European centers. Primary resistance was defined as progressive disease as best response or stable disease lasting <6 months. Outcomes of second-line platinum-based chemotherapy alone or combined with ICI were compared. The primary endpoint was progression-free survival 2, defined as time from first-line ICI initiation

SUBMITTER: De Giglio A 

PROVIDER: S-EPMC12666335 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature